Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of ustekinumab and golimumab in axial spondyloarthritis (ankylosing spondylitis)
2015-000288-16Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ankylosing spondylitis (AS) and axial spondyloarthritis (axSpA) comparing ustekinumab, golimumab and placebo (3 arms). Primary endpoint: ASAS 40 response at week 24. Started Jun 2015; status: completed.
02
Drugs
ustekinumabgolimumab
03
Conditions
ankylosing spondylitis (AS)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2015-000288-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000288-16.